Evidence map›Paper›PMID 42666545›Full record

ArticleUrology case reports2026

Myeloid sarcoma of prostate: A case report and literature review.

Li Huang, Congbo Chen, Hao Li, Shengtao Ling, Hongxia Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Li HuangDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Congbo ChenDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Hao LiDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Shengtao LingDepartment of Urology, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Hongxia ChenBiomedicine of Institute, Taihe Hospital, Hubei University of Medicine, Regulatory Mechanism and Targeted Therapy for Liver Cancer Shiyan Key Laboratory, Hubei Provincial Clinical Research Center for Precise Diagnosis and Treatment of Liver Cancer, Shiyan, 442000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary myeloid sarcoma arising in the prostate is an exceptionally rare extramedullary manifestation of acute myeloid leukemia. Its nonspecific clinical presentation frequently leads to diagnostic delay or misdiagnosis. This report aims to enhance clinical awareness and diagnostic accuracy through a detailed analysis of a representative case and a systematic review of the existing literature. We report a 74-year-old male initially misdiagnosed as benign prostatic hyperplasia, confirmed post-PKRP by MPO-positive pathology. He received AML-directed systemic chemotherapy after transfer to hematology. Normal PSA and MPO positivity aid diagnosis; obstruction relief plus AML-regimen chemotherapy is core. Lysozyme testing was not performed.

Indexed as

Benign prostatic hyperplasiaDiagnosisMyeloid sarcomaMyeloperoxidaseTreatment

Identifiers

PMID42666545
PMCPMC13522236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.